Could it slow decline?Peter Byrne/PABy New Scientist staff and Press AssociationAn antibody has significantly reduced levels of beta amyloid protein in people with Alzheimer’s disease, spurring hopes for a new class of drugs that can treat the condition. Aducanumab is a drug based on an antibody discovered by comparing the blood of healthy older people...